Intranasal antisense therapy: Preclinical models with a clinical future?

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 2, 2007, Pages 119-125

  Bitko, Vira ^a   Barik, Sailen ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Allergy; Antisense oligonucleotides; Asthma; Intranasal delivery; RNA interference; siRNA; Viral respiratory diseases

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; INFLUENZA VACCINE; SMALL INTERFERING RNA;

ALLERGIC ASTHMA; ALLERGY; ANTISENSE THERAPY; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; HUMAN; INFLUENZA; LUNG FIBROSIS; LUNG INJURY; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; RNA INTERFERENCE; SEVERE ACUTE RESPIRATORY SYNDROME; TARGET ORGAN; VIRAL RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL THERAPY; DRUG EVALUATION, PRECLINICAL; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RESPIRATORY TRACT DISEASES; RNA INTERFERENCE;

EID: 34247178673     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Nyce JW, Metzger WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385(6618):721-725. • The first report of the use of RASONS against asthma in an animal model.
2. Allakhverdi Z, Allam M, Renzi PM: Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common β chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med (2002) 165(7):1015-1021.
3. Ali S, Leonard SA, Kukoly CA, Metzger WJ, Wooles WR, McGinty JF, Tanaka M, Sandrasagra A, Nyce JW: Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am J Respir Crit Care Med (2001) 163(4):989-993.
4. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS: Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med (2005) 171(6):571-578.
5. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H et al: Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med (2001) 193(11):1247-1260.
6. Verma M, Baraniuk J, Blass C, Ali M, Yuta A, Biedlningmaier J, Davidson EA: CFTR antisense phosphorothioate oligodeoxynucleotides (S-ODNs) induce tracheo-bronchial mucin (TBM) mRNA expression in human airway mucosa. Glycoconjugate J (1999) 16(1):7-11.
7. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N et al: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med (2005) 11(9):944-951. • The first report of using RNAi against SARS-CoV in an animal model.
8. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med (2005) 11(1):50-55. • This research formed the basis of the first clinical trial (by Alnylam) of nasal siRNA against RSV.
9. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA (2004) 101(23):8676-8681.
10. Tompkins SM, Lo CY, Tumpey TM, Epstein SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA (2004) 101(23):8682-8686.
11. Barik S: Silence of the transcripts: RNA interference in medicine. J Mol Med (2005) 83(10):764-773.
12. Barik S, Bitko V: Prospects of RNA interference therapy in respiratory viral diseases: Update 2006. Expert Opin Biol Ther (2006) 6(11):1151-1160.
13. Crooke ST: Progress in antisense technology. Annu Rev Med (2004) 55:61-95.
14. Tanaka M, Nyce JW: Respirable antisense oligonucleotides: A new drug class for respiratory disease. Respir Res (2001) 2(1):5-9.
15. Minshull J, Hunt T: The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res (1986) 14(16):6433-6451. • The first study demonstrating that antisense oligonucleotides appear to act specifically by directing RNase H cleavage and destabilizing their complementary mRNA.
16. Walder RY, Walder JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA (1988) 85(14):5011-1015.
17. Dagle JM, Walder JA, Weeks DL: Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: Studies of An2 and cyclin in embryogenesis. Nucleic Acids Res (1990) 18(16):4751-4757.
18. Henry SP, Geary RS, Yu R, Levin AA: Drug properties of secondgeneration antisense oligonucleotides: How do they measure up to their predecessors? Curr Opin Investig Drugs (2001) 2(10):1444-1449.
19. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM: Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 268(19):14514-14522.
20. Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Melgaard M, Olsen CE, Wengel J: LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron (1998) 54(14):3607-3630.
21. Braasch DA, Corey DR: Locked nucleic acid (LNA): Fine-tuning the recognition of DNA and RNA. Chem Biol (2001) 8(1):1-7.
22. Elayadi AN, Corey DR: Application of PNA and LNA oligomers to chemotherapy. Curr Opin Investig Drugs (2001) 2(4):558-561.
23. Dias N, Dheur S, Nielsen PE, Gryaznov S, Van Aerschot A, Herdewijn P, Helene C, Saison-Behmoaras TE: Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J Mol Biol (1991) 294(2):403-416.
24. Baker BF, Monia BP: Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta (1999) 1489(1):3-18.
25. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 7(3):187-195.
26. Gryaznov SM, Lloyd DH, Chen JK, Schultz RG, DeDionisio LA, Ratmeyer L, Wilson WD: Oligonucleotide N3′→P5′ phosphoramidates. Proc Nat Acad Sci USA (1995) 92(13):5798-5802.
27. Chen JK, Schultz RG, Lloyd DH, Gryaznov SM: Synthesis of oligodeoxyribonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res (1995) 23(14):2661-2668.
28. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen JK, Koziolkiewicz M, Calabretta B: Oligonucleotide N3′→ P5′ phosphoramidates as antisense agents. Nucleic Acids Res (1996) 24(8):1508-1514.
29. Skorski T, Perrotti D, Nieborowska-Skorska M, Gryaznov S, Calabretta B: Antileukemia effect of c-myc N3′→P5′ phosphoramidate antisense oligonucleotides in vivo. Proc Natl Acad Sci USA (1997) 94(8):3966-3971.
30. Dias N, Stein CA: Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther (2002) 1(5):347-355. • This review summarized various chemical modifications of antisense oligonucleotides and discussed advantages of various chemical modifications.
31. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM: Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem (1999) 274(3):1715-1722.
32. Giles RV, Spiller DG, Grzybowski J, Clark RE, Nicklin P, Tidd DM: Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res (1998) 26(7):1567-1575.
33. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA (1997) 94(6):2620-2625.
34. Shen LX, Kandimalla ER, Agrawal S: Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorg Med Chem (1998) 6(10):1695-1705.
35. Grindel JM, Musick TJ, Jiang Z, Roskey A, Agrawal S: Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev (1998) 8(1): 43-52.
36. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol (1995) 49(7):929-939.
37. Templin MV, Levin AA, Graham MJ, Aberg PM, Axelsson BI, Butler M, Geary RS, Bennett CF: Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev (2000) 10(5):359-368.
38. Popescu FD: Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med (2005) 9(4):840-853.
39. Karras JG, Crosby JR, Guha M, Tung D, Miller DA, Gaarde WA, Geary RS, Monia BP, Gregory SA: Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice. Am J Respir Cell Mol Biol (2007) 36(3):276-285.
40. Bentley AM, Menz G, Storz C, Robinson DS, Bradley B, Jeffery PK, Durham SR, Kay AB: Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis (1992) 146(2):500-506.
41. Bjornsdottir US, Cypcar DM: Asthma: An inflammatory mediator soup. Allergy (1999) 54(49):55-61.
42. Busse WW, Lemanske RF Jr: Asthma. N Engl J Med (2001) 344(5):350-362.
43. Herrick CA, Bottomly K: To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol (2003) 3(5):405-412.
44. Ting CN, Olson MC, Barton KP, Leiden JM: Transcription factor GATA-3 is required for development of the T-cell lineage. Nature (1996) 384(6608):474-478.
45. Zheng W, Flavell RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 89(4):587-596.
46. Justice JP, Borchers MT, Lee JJ, Rowan WH, Shibata Y, Van Scott MR: Ragweed-induced expression of GATA-3, IL-4, and IL-5 by eosinophils in the lungs of allergic C57BL/6J mice. Am J Physiol Lung Cell Mol Physiol (2002) 282(2):L302-L309.
47. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H et al: Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med (2001) 193(11):1247-1260.
48. Finotto S, Buerke M, Lingnau K, Schmitt E, Galle PR, Neurath MF: Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol (2001) 107(2):279-286.
49. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS: Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med (2005) 171(6):571-578.
50. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T: The Syk protein tyrosine kinase is essential for Fc-γ receptor signaling in macrophages and neutrophils. Mol Cell Biol (1998) 18(7):4209-4220.
51. Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL: A critical role for Syk in signal transduction and phagocytosis mediated by Fc-γ receptors on macrophages. J Exp Med (1997) 186(7):1027-1039.
52. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, Schreiber AD, Befus AD: Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol (2002) 169(2):1028-1036.
53. Blount RE Jr, Morris JA, Savage RE: Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med (1956) 92(3):544-549.
54. Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus. In: Field's Virology. Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Strans SE (Eds), Lippincott-Raven, Philadelphia, PA, USA (1996):1313-1351.
55. Fowlkes AL, Fry AM, Anderson LJ: Brief report: Respiratory syncytial virus activity - United States, 2005-2006. Morb Mortal Wkly Rep (2006) 55(47):1277-1279.
56. Sidwell RW, Barnard DL: Respiratory syncytial virus infections: Recent prospects for control. Antiviral Res (2006) 71(2-3):379-390.
57. Maggon K, Barik S: New drugs and treatment for respiratory syncytial virus. Rev Med Virol (2004) 14(3):149-168. • A comprehensive review on existing treatments for RSV.
58. Player MR, Barnard DL, Torrence PF: Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc Natl Acad Sci USA (1998) 95(15):8874-8879.
59. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE: Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res (1997) 33(3):201-213.
60. Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH, Cramer H: Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology (2002) 292(1):70-77. • The first report of the successful intranasal application of an unusual antisense ODN against respiratory infection in an animal model.
61. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806-811. •• The discovery of RNAi is reported. This research led to the Nobel Prize (2006) being awarded to the researchers.
62. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B, Melo LG, Zhang L, Ingwall JS, Dzau VJ et al: Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res (2001) 89(2):168-173.
63. Otterbein LE, Choi AM: Heme oxygenase: Colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol (2000) 279(6):L1029-L1037.
64. Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AM: Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest (1999) 103(7):1047-1054.
65. Abraham NG, Lavrovsky Y, Schwartzman ML, Stoltz RA, Levere RD, Gerritsen ME, Shibahara S, Kappas A: Transfection of the human heme oxygenase gene into rabbit coronary microvessel endothelial cells: Protective effect against heme and hemoglobin toxicity. Proc Natl Acad Sci USA (1995) 92(15):6798-6802.
66. Lee PJ, Otterbein LE, Sethi J, Sasidhar M, Choi AM: Carbon monoxide heme oxygenase-1 in lung disease. In: Disease Markers in Exhaled Breath. Marczin N, Kharitonov S, Yacoub M, Barnes P (Eds), Marcel Dekker Inc, New York, NY, USA (2002):117-127.
67. Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, Lee PJ: Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem (2004) 279(11):10677-10684.
68. Qureshi ST, Zhang X, Aberg E, Bousette N, Giaid A, Shan P, Medzhitov RM, Lee PJ: Inducible activation of TLR4 confers resistance to hyperoxia-induced pulmonary apoptosis. J Immunol (2006) 176(8):4950-4958.
69. Matsuyama W, Watanabe M, Shirahama Y, Oonakahara K, Higashimoto I, Yoshimura T, Osame M, Arimura K: Activation of discoidin domain receptor 1 on CD14-positive bronchoalveolar lavage fluid cells induces chemokine production in idiopathic pulmonary fibrosis. J Immunol (2005) 174(10):6490-6498.
70. Matsuyama W, Watanabe M, Shirahama Y, Mitsuyama H, Higashimoto I, Osame M, Arimura K: Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis. Am J Pathol (2006) 168(3):866-877.
71. Avivi-Green C, Singal M, Vogel WF: Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med (2006) 174(4):420-427.
72. Matsuyama W, Watanabe M, Shirahama Y, Hirano R, Mitsuyama H, Higashimoto I, Osame M, Arimura K: Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J Immunol (2006) 176(3):1928-1936.
73. Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol (2001) 1:34. •• This is the first report of RNAi as an antiviral agent.
74. Mackie PL: The classification of viruses infecting the respiratory tract. Paediatr Respir Rev (2003) 4(2):84-90.
75. The influenza (flu) viruses: Centers for Disease Control and Prevention, Atlanta, GA, USA (2006). http://www.cdc.gov/flu/about/fluviruses. htm
76. Nichol KL, Wuorenma J, von Sternberg T: Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med (1998) 158(16):1769-1776.
77. Glezen WP, Decker M, Perrotta DM: Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis (1987) 136(3):550- 555.
78. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA (2003) 100(5):2718-2723.
79. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med (2005) 11(1):56-62.
80. Teng MN, Collins PL: Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol (1999) 73(1):466-473.
81. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N: Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology (2000) 273(1):210-218.
82. Teng MN, Whitehead SS, Bermingham A, St Claire M, Elkins WR, Murphy BR, Collins PL: Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol (2000) 74(19):9317-9321.
83. Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB et al: The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 193(4):573-581.
84. Lo MS, Brazas RM, Holtzman MJ: Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and α/β interferon responsiveness. J Virol (2005) 79(14):9315-9319.
85. Kotelkin A, Belyakov IM, Yang L, Berzofsky JA, Collins PL, Bukreyev A: The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J Virol (2006) 80(12):5958-5967.
86. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC: Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology (2006) 344(2):328-339.
87. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S: Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-κB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol (2007) 81(4):1786-1795.
88. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC et al: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 361(9366): 1319-1325.
89. Basic information about SARS: Centers for Disease Control and Prevention, Atlanta, GA, USA (2005). http://www.cdc.gov/ncidod/sars/ factsheet.htm
90. Gillim-Ross L, Subbarao K: Emerging respiratory viruses: Challenges and vaccine strategies. Clin Microbiol Rev (2006) 19(4):614-636.
91. Qin C, Wang J, Wei Q, She M, Marasco WA, Jiang H, Tu X, Zhu H, Ren L, Gao H, Guo L et al: An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol (2005) 206(3):251-259.
92. Zheng BJ, Guan Y, Tang Q, Du C, Xie FY, He ML, Chan KW, Wong KL, Lader E, Woodle MC, Lu PY et al: Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther (2004) 9(3):365-374.
93. Alnylam Pharmaceuticals Inc: Alnylam reports phase I clinical safety data for ALN-RSV01, an RNAi therapeutic for the treatment of RSV infection. (2006):April 30.
94. Therapeutic pipeline: Sirna Therapeutics Inc, San Francisco, CA, USA (2007). http://www.sirna.com/wt/page/product_pipeline
95. Pipeline: Nastech Pharmaceutical Co, Bothell, WA, USA (2007). http://www.nastech.com/nastech/pipeline
96. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther (2006) 14(4):476-484.
97. Massaro D, Massaro GD, Clerch LB: Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol (2004) 287(5):L1066-L1070.